Randomized, double-blinded multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase (GE-0943), and intracoronary urokinase in patients with acute myocardial infarction

Circulation. 1988 Oct;78(4):899-905. doi: 10.1161/01.cir.78.4.899.

Abstract

Coronary recanalization rates and changes in the coagulation and fibrinolysis system were evaluated in a randomized fashion in patients with acute myocardial infarction after intracoronary administration of single-chain urokinase-type plasminogen activator (pro-urokinase: GE-0943) or urokinase. Three groups of patients were studied: group H (n = 50), 6,000 units pro-urokinase i.c.; group L (n = 44), 3,000 units pro-urokinase i.c.; and group U (n = 54), 960,000 IU urokinase i.c. Coronary recanalization rates determined angiographically after 45 minutes of intracoronary infusion averaged 90% in group H, 59% in group L, and 61% in group U. The differences were statistically significant between group H and the latter two groups. Pro-urokinase affected plasma proteins of the fibrinolytic system to a lesser degree than urokinase. Bleeding complications were present in one patient in group L, in none in group H, and in five in group U. Thus, intracoronary administration of 6,000 units pro-urokinase is more effective in coronary thrombolysis and causes less systemic fibrinogenolysis than intracoronary administration of urokinase.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Coronary Vessels
  • Double-Blind Method
  • Enzyme Precursors / therapeutic use
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Japan
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Myocardial Infarction / drug therapy*
  • Plasminogen Activators / therapeutic use*
  • Random Allocation
  • Urokinase-Type Plasminogen Activator / therapeutic use*

Substances

  • Enzyme Precursors
  • Fibrinolytic Agents
  • Plasminogen Activators
  • Urokinase-Type Plasminogen Activator